Sanofi (NASDAQ:SNY) has stopped shipping its anti-cholesterol therapy Praluent, developed with Regeneron (NASDAQ:REGN), as ...

Sanofi said on Tuesday it had stopped supplying Praluent, a popular cholesterol drug jointly developed by the French ...

Sanofi is pulling its PCSK9 drug Praluent from the Chinese market. President Donald Trump said U.S. pharmaceutical tariffs ...

Praluent-treated patients started the trial on 75 mg every 2 weeks, and switched to 150 mg every 2 weeks if their LDL-C levels remained above 50 mg/dL (n=2,615).

Sanofi (NASDAQ:SNY) announced on Tuesday that it has stopped supplying Praluent in China due to limited availability of the popular cholesterol medication.

Praluent and a similar drug, Amgen's Repatha, work in a different way and lower cholesterol much more. Patients give themselves shots of the medicine once or twice a month.

Praluent is supplied in 2 dosage strengths, 75mg/mL and 150mg/mL, in a single-dose prefilled pen. In children aged 8 to 11 years, Praluent should be given by a caregiver following proper training.

I then started Praluent injections twice a month to control my cholesterol, which has been incredibly effective — maybe even too effective — and is the purpose of my writing to you.

UnitedHealth Group Inc. UNH 0.32% said Friday that Praluent, developed by Regeneron Pharmaceuticals Inc. REGN -0.07% and Sanofi SA, SAN 0.99% will be the preferred drug for a new class of ...

On the primary endpoint, Praluent reduced the overall risk of MACE by 15% (HR=0.85, CI: 0.78-0.93, p=0.0003). The MACE composite endpoint includes patients who experienced a heart attack, ischemic ...

The second issue is your very low LDL level, and the data for LDL levels is firmly on the side of the cardiologists you spoke with. The lower the LDL, the lower the risk of heart disease, and levels ...